Study of Potencial Cell Therapy Treated its 20th Patient
Cytori Therapeutics recently announced that its Phase 3 STAR clinical trial, evaluating the efficacy and safety of Cytori Cell Therapy in scleroderma patients with hand impairment, has treated its 20th patient to reach 25 percent of its enrollment and treatment goal. The trial is continuing on the recommendation of an independent monitoring committee that evaluated safety data obtained from the first 10 patients.
The STAR clinical trial (NCT02396238), currently recruiting participants, is a placebo-controlled Phase 3 study of Cytori Cell Therapy (ECCS-50) injected subcutaneously into the fingers of scleroderma patients who have experienced hand dysfunction due to the disease.
Learn more about scleroderma here: http://bit.ly/learnscleroderma